NDC 42292-024-01 - Gabapentin
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 42292-024
- Requested NDC
- 42292-024-01
- Package NDCs from labels
- 42292-024-01, 42292-024-20
- Manufacturer
- Mylan Institutional Inc.
- Effective date
- 2019-12-30
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Gabapentin - Mylan Institutional Inc. | Mylan Institutional Inc. | 2019-12-30 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 42292-024-01 | EA - Each | 42292-024 | 20770548-0dad-46a4-a1d1-f6e9b6971b55 | 1 | 2016-09-02 |
| 42292-024-20 | EA - Each | 42292-024 | 398d182f-a77b-4fc5-9cba-7dee40f3ac4d | 1 | 2016-09-02 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| GABAPENTIN | GABAPENTIN | Preferred Pharmaceuticals Inc. | 11645bd6-7cfe-49b2-9292-2e4b0dbb84ae | 2025-06-04 | Warnings, Adverse reactions | 6CW7F3G59X |
| gabapentin | GABAPENTIN | Rising Pharma Holdings, Inc. | 969cccfc-e56a-49da-9d36-47c0c3fad7f8 | 2025-06-03 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | PAI Holdings, LLC dba PAI Pharma | 6d3fd1f9-c831-4262-af10-291838a53541 | 2025-05-31 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Rising Pharma Holdings, Inc. | 8215da86-d7af-4980-b6d6-4bd46f6bfeaf | 2025-05-30 | Warnings, Adverse reactions | 310433 6CW7F3G59X |
| Gabapentin | GABAPENTIN | ATLANTIC BIOLOGICALS CORP. | 5969f1a8-d6d5-4967-add5-4e2492354d7b | 2025-05-27 | Warnings, Adverse reactions | 6CW7F3G59X |
| GABAPENTIN | GABAPENTIN | Camber Pharmaceuticals, Inc. | 0ce53f62-1738-43f4-9a2e-c5dc42a91d09 | 2025-05-26 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | St. Mary's Medical Park Pharmacy | 7d3fc163-25f0-2c61-e053-2991aa0a76e9 | 2025-05-23 | Warnings, Adverse reactions | 310433 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Amneal Pharmaceuticals LLC | 772d9e7a-3811-455a-99e6-f2a3d0769b9b | 2025-05-13 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Aurobindo Pharma Limited | 1a619a14-0b63-4cba-80e7-474c9a1c90b9 | 2025-05-12 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Aurobindo Pharma Limited | 25cf6c40-a239-4dd0-9cad-28da84d285db | 2025-05-09 | Warnings, Adverse reactions | ANDA200651 65862-523 65862-524 310433 310434 700d09f5-99cc-492d-ab49-442f674d9c5d 25cf6c40-a239-4dd0-9cad-28da84d285db 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Proficient Rx LP | 3c8dca11-78ab-45c1-8bb2-89a41ea5dfa9 | 2025-05-01 | Warnings, Adverse reactions | 6CW7F3G59X |
| GABAPENTIN | GABAPENTIN | Exelan Pharmaceuticals, Inc. | 41d1ead3-046e-4abf-ae0a-cb126a1f5848 | 2025-05-01 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Actavis Pharma, Inc. | 5969871e-6c71-4c37-9d63-370718ccc80c | 2025-05-01 | Warnings, Adverse reactions | 6CW7F3G59X |
| GABAPENTIN | GABAPENTIN | Cipla USA Inc. | 9e4eca9c-6a2c-4ede-a252-1a27094bf594 | 2025-05-01 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Direct_Rx | 30a2ed14-dcda-f972-e063-6294a90a417c | 2025-04-23 | Warnings, Adverse reactions | 310434 6CW7F3G59X |
| Gabapentin | GABAPENTIN | McKesson Corporation dba Sky Packaging | 23eb133e-2f74-4219-9892-0a8e770ec032 | 2025-04-17 | Warnings, Adverse reactions | 6CW7F3G59X |
| GABAPENTIN | GABAPENTIN | Mylan Pharmaceuticals Inc. | cff7de45-148b-4e96-88fd-6052bf75b5f7 | 2025-04-12 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Westminster Pharmaceuticals, LLC | 3ad96553-73a4-4a9b-8a89-10a29b794ed3 | 2025-04-04 | Warnings, Adverse reactions | 6CW7F3G59X |
| GABAPENTIN | GABAPENTIN | Proficient Rx LP | 7fcce531-bf7c-43b6-bea9-8f0602842c53 | 2025-04-01 | Warnings, Adverse reactions | 310433 6CW7F3G59X |
| GABAPENTIN | GABAPENTIN | Coupler LLC | 3133c863-d33b-c9d7-e063-6294a90ae898 | 2025-03-25 | Warnings, Adverse reactions | 310433 6CW7F3G59X |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.